VEL 0230

Drug Profile

VEL 0230

Alternative Names: NC-2300; VEL-0230

Latest Information Update: 08 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Chemiphar
  • Developer Velcura Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Multiple myeloma; Osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 08 Feb 2011 No development reported - Phase-I for Multiple myeloma in USA (PO)
  • 08 Feb 2011 No development reported - Phase-I for Osteoporosis in USA (PO)
  • 08 Feb 2011 No development reported - Phase-I for Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top